Max Rosett - Oct 2, 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role: SVP Operations
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Stock symbol: IMNM
Transactions as of: Oct 2, 2023
Transactions value $: $0
Form type: 3
Date filed: 10/12/2023, 06:36 PM
Next filing: Jan 31, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	IMNM	Common Stock						19.9K	Oct 2, 2023	Direct	F1

Showing 1 to 1 of 1 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	IMNM	Stock Option (Right to Buy)							Oct 2, 2023	Common Stock	39.7K	$1.35	Direct	F2
holding	IMNM	Stock Option (Right to Buy)							Oct 2, 2023	Common Stock	134K	$1.06	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Mr. Rosett was appointed as SVP Operations of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Mr. Rosett being appointed an executive officer of the Issuer, Mr. Rosett exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer.
F2	25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.

Content

Mr. Rosett was appointed as SVP Operations of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Mr. Rosett being appointed an executive officer of the Issuer, Mr. Rosett exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer.

25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.

Remarks:

See Attached Exhibit 24